A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. European Lung Cancer Working Party.

[1]  J. Lafitte,et al.  Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Calvert,et al.  The use of pharmacokinetics to improve the treatment of ovarian cancer: combination paclitaxel (Taxol®)–carboplatin , 1997 .

[3]  Calvert Ah.  A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. , 1997 .

[4]  M. Fiorentino,et al.  Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer: A phase II trial , 1996, Cancer.

[5]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Millward,et al.  Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute. , 1996, Australian and New Zealand journal of medicine.

[7]  G. Houin,et al.  Prediction of carboplatin clearance from standard morphological and biological patient characteristics. , 1995, Journal of the National Cancer Institute.

[8]  M. Egorin.  Further refinement of carboplatin dosing. , 1995, Journal of the National Cancer Institute.

[9]  J. Sculier,et al.  Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Paesmans,et al.  Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Langenberg,et al.  Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[13]  E Wiltshaw,et al.  Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Benfield,et al.  Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. , 1989, Drugs.

[15]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[16]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[17]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[18]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .